Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953968008> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2953968008 endingPage "S321" @default.
- W2953968008 startingPage "S321" @default.
- W2953968008 abstract "In Canada, all public (provincial, territorial, and federal) and private drug payers require budget impact analyses (BIAs) to make funding decisions. Guidelines for conducting BIAs have been developed in Canada, as well as from international and national agencies. The alignment of Canadian guidelines with recommendations from other BIA guidelines is unknown. To review guidelines for BIAs and identify similarities and differences from the standpoint of Canadian payers. A literature review was performed to identify English-language guidelines for BIAs in Canada, and from international health economics societies and existing and proposed countries used for reference-based pricing of patented drugs in Canada. Specifically, guidelines from France, Germany, Italy, Sweden, Switzerland, the UK, and the US, as well as Australia, Belgium, Japan, the Netherlands, Norway, South Korea, and Spain were sought. Recommendations on key elements for conducting BIAs were extracted from the available guidelines and compared. The literature review identified one national and three provincial guidelines (Alberta, Manitoba, and Ontario) from Canada, seven other national guidelines (Australia, Belgium, France, Germany, the Netherlands, UK, and US), and one recommendation for good practices from ISPOR. The Canadian guidelines were largely consistent with recommendations from other agencies for model structure, discounting, population, estimating market shares, drug costs, off-label use, presentation of results, uncertainty assessment, and model validation. Differences between the Canadian and other guidelines were observed in several key elements, including perspective, time horizon, comparators, and the inclusion of non-drug costs. Among the Canadian guidelines, there was variability in terms of guidance for province-specific population size, comparators, and drug costs. Canada has unique requirements for BIAs compared with other countries. The specific requirement for multiple payer-specific BIAs is likely due to the unique Canadian drug reimbursement landscape where drugs are funded by siloed drug payers rather than a healthcare payer." @default.
- W2953968008 created "2019-07-12" @default.
- W2953968008 creator A5054951046 @default.
- W2953968008 creator A5066233661 @default.
- W2953968008 creator A5088524760 @default.
- W2953968008 date "2019-05-01" @default.
- W2953968008 modified "2023-09-27" @default.
- W2953968008 title "PNS210 REVIEW OF CANADIAN VERSUS OTHER GUIDELINES FOR CONDUCTING BUDGET IMPACT ANALYSIS: DO CANADIAN GUIDELINES DIFFER AND WHY?" @default.
- W2953968008 doi "https://doi.org/10.1016/j.jval.2019.04.1567" @default.
- W2953968008 hasPublicationYear "2019" @default.
- W2953968008 type Work @default.
- W2953968008 sameAs 2953968008 @default.
- W2953968008 citedByCount "0" @default.
- W2953968008 crossrefType "journal-article" @default.
- W2953968008 hasAuthorship W2953968008A5054951046 @default.
- W2953968008 hasAuthorship W2953968008A5066233661 @default.
- W2953968008 hasAuthorship W2953968008A5088524760 @default.
- W2953968008 hasBestOaLocation W29539680081 @default.
- W2953968008 hasConcept C100001284 @default.
- W2953968008 hasConcept C121955636 @default.
- W2953968008 hasConcept C144133560 @default.
- W2953968008 hasConcept C160735492 @default.
- W2953968008 hasConcept C162118730 @default.
- W2953968008 hasConcept C162324750 @default.
- W2953968008 hasConcept C17744445 @default.
- W2953968008 hasConcept C2908647359 @default.
- W2953968008 hasConcept C50522688 @default.
- W2953968008 hasConcept C524218345 @default.
- W2953968008 hasConcept C71924100 @default.
- W2953968008 hasConcept C99454951 @default.
- W2953968008 hasConceptScore W2953968008C100001284 @default.
- W2953968008 hasConceptScore W2953968008C121955636 @default.
- W2953968008 hasConceptScore W2953968008C144133560 @default.
- W2953968008 hasConceptScore W2953968008C160735492 @default.
- W2953968008 hasConceptScore W2953968008C162118730 @default.
- W2953968008 hasConceptScore W2953968008C162324750 @default.
- W2953968008 hasConceptScore W2953968008C17744445 @default.
- W2953968008 hasConceptScore W2953968008C2908647359 @default.
- W2953968008 hasConceptScore W2953968008C50522688 @default.
- W2953968008 hasConceptScore W2953968008C524218345 @default.
- W2953968008 hasConceptScore W2953968008C71924100 @default.
- W2953968008 hasConceptScore W2953968008C99454951 @default.
- W2953968008 hasLocation W29539680081 @default.
- W2953968008 hasOpenAccess W2953968008 @default.
- W2953968008 hasPrimaryLocation W29539680081 @default.
- W2953968008 hasRelatedWork W1539921135 @default.
- W2953968008 hasRelatedWork W155998631 @default.
- W2953968008 hasRelatedWork W164362287 @default.
- W2953968008 hasRelatedWork W1988734249 @default.
- W2953968008 hasRelatedWork W1991279284 @default.
- W2953968008 hasRelatedWork W2348075735 @default.
- W2953968008 hasRelatedWork W2748952813 @default.
- W2953968008 hasRelatedWork W2899084033 @default.
- W2953968008 hasRelatedWork W3135270396 @default.
- W2953968008 hasRelatedWork W3185280790 @default.
- W2953968008 hasVolume "22" @default.
- W2953968008 isParatext "false" @default.
- W2953968008 isRetracted "false" @default.
- W2953968008 magId "2953968008" @default.
- W2953968008 workType "article" @default.